Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

InMed Pharmaceuticals (INM) Net Margin (2021 - 2025)

InMed Pharmaceuticals has reported Net Margin over the past 5 years, most recently at 247.29% for Q4 2025.

  • For Q4 2025, Net Margin fell 1566.0% year-over-year to 247.29%; the TTM value through Dec 2025 reached 170.07%, down 645.0%, while the annual FY2025 figure was 165.14%, 180.0% up from the prior year.
  • Net Margin for Q4 2025 was 247.29% at InMed Pharmaceuticals, down from 154.17% in the prior quarter.
  • Over five years, Net Margin peaked at 14.56% in Q2 2023 and troughed at 1615.6% in Q4 2021.
  • A 5-year average of 457.91% and a median of 193.09% in 2023 define the central range for Net Margin.
  • Biggest five-year swings in Net Margin: soared 151431bps in 2023 and later tumbled -13590bps in 2024.
  • Year by year, Net Margin stood at 1615.6% in 2021, then skyrocketed by 72bps to 446.61% in 2022, then surged by 73bps to 119.19% in 2023, then crashed by -94bps to 231.63% in 2024, then dropped by -7bps to 247.29% in 2025.
  • Business Quant data shows Net Margin for INM at 247.29% in Q4 2025, 154.17% in Q3 2025, and 137.07% in Q2 2025.